TriOar's platform technologies can be applied to
various targets and diverse modalities
various targets and diverse modalities
Antibody-Drug Conjugates
| PLATFORMS | PROGRAM | INDICATION | DISCOVERY | PRECLINICAL | CLINICAL STAGE |
|---|---|---|---|---|---|
| TROSIG™ | AD-01(HER2) | Breast cancer |
ADC 1
Highly Efficacious Antibody-Drug Conjugate Targeting HER2-Positive Breast and Gastric Cancers.
|
||
| AD-02 | Gastric cancer |
ADC 2
Targeting a Molecule with Extremely Limited Expression in Normal Cells and Potential Relevance to Gastric/Pancreatic Cancer.
|
|||
| TROSIG™ TROCAD™ |
TD-01 | Triple-negative breast cancer |
TODC 1
Novel Antibody-Drug Conjugate targeting Triple-Negative Breast Cancer with improved TI.
|
||
| TD-02 | Solid cancer |
TODC 2
Novel Antibody-Drug Conjugate for a Challenging Target with Low Efficacy as an Indication for Advanced Malignant Solid Tumor.
|
|||
Immuno-Oncology
| PLATFORMS | PROGRAM | INDICATION | DISCOVERY | PRECLINICAL | CLINICAL STAGE |
|---|---|---|---|---|---|
| TROCAD™ | IO-01 | Solid cancer |
IO 1
Multi-Specific Antibody Targeting a Broad Solid Tumor Spectrum with Reduced Hematotoxicity, Simultaneously Exhibiting TME-Specific Action.
|
||
| IO-02 | R/R solid cancer |
IO 2
Multi-Specific Antibody with a Novel Format to Reduces Systemic Toxicity and Enhances Targeted Efficacy in Cancer.
|
|||
